Literature DB >> 12717355

Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection, and survival.

Anthony P Polednak1.   

Abstract

BACKGROUND: The frequency of bilateral synchronous breast cancer (BSBC) is reportedly about 1%-3%, but there is limited information from population-based cancer registries regarding the clinical and prognostic features of these cancers.
METHODS: The population-based Connecticut Tumor Registry (CTR), which is part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program of registries, was used to identify BSBC (ie, a second cancer diagnosed within 3 months of the first). Information was obtained on the method of detection of BSBC, and clinical characteristics and survival (through 2000) were compared with unilateral cases.
RESULTS: Of 15,542 patients reported to the CTR, 300 (1.9%) had BSBC. BSBC was detected most often by mammography of both breasts (35%) or contralateral mammography after a palpable first cancer (18%). Compared to unilateral cases, BSBC patients did not differ in age or stage at diagnosis, but lobular histology was statistically significantly more frequent and use of total mastectomy (vs lesser surgery) was more common. Although length of follow-up was limited, risk of death was statistically, significantly higher among BSBC than unilateral patients. Among BSBC patients, risk of death was higher among those with cancers detected by breast exam/symptoms versus mammography. CONCLUSIONS; While uncommon, BSBCs differ from unilateral cancer in histology and survival, and their study emphasizes the opportunity for detection of contralateral cancers at an early stage.

Entities:  

Mesh:

Year:  2003        PMID: 12717355     DOI: 10.1067/msy.2003.110

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Authors:  Xuesong Han; Tongzhang Zheng; Francine M Foss; Qing Lan; Theodore R Holford; Nathaniel Rothman; Shuangge Ma; Yawei Zhang
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

2.  Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer.

Authors:  Yan-Xia Shi; Qing Xia; Rou-Jun Peng; Zhong-Yu Yuan; Shu-Sen Wang; Xin An; Ye Cao; Yu-Ting Tan; Ying Jin; Xiu-Yu Cai; Yue-Li Sun; Xiao-Yu Teng; Dong-Geng Liu; Wen-Qi Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-12       Impact factor: 4.553

3.  Multigene assessment of genetic risk for women for two or more breast cancers.

Authors:  Jeffrey N Weitzel; John Kidd; Ryan Bernhisel; Susan Shehayeb; Paul Frankel; Kathleen R Blazer; Diana Turco; Bita Nehoray; Kim McGreevy; Kira Svirsky; Krystal Brown; Anna Gardiner; Mary Daly; Elisha Hughes; Shelly Cummings; Jennifer Saam; Thomas P Slavin
Journal:  Breast Cancer Res Treat       Date:  2021-04-07       Impact factor: 4.624

Review 4.  [The place of magnetic resonance imaging in lobular carcinoma of the breast].

Authors:  Wail Bouzoubaa; Meryem Laadioui; Fatime Zahra Fdili Alaoui; Sofia Jayi; Hakima Bouguern; Hikmat Chaara; Moulay Abdelilah Melhouf
Journal:  Pan Afr Med J       Date:  2014-05-06

5.  [Synchronous bilateral breast cancer: experiences in the Mohammed VI Cancer Treatment Center, CHU Ibn Rochd, Casablanca].

Authors:  Ahmadaye Ibrahim Khalil; Karima Bendahhou; Houriya Mestaghanmi; Rachid Saile; Abdellatif Benider
Journal:  Pan Afr Med J       Date:  2016-10-27

6.  Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature.

Authors:  Ambrogio P Londero; Sergio Bernardi; Serena Bertozzi; Vito Angione; Giuliana Gentile; Cinzia Dri; Antonio Minucci; Filippo Caponnetto; Roberto Petri
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

7.  Genomic imbalances and MYB fusion in synchronous bilateral adenoid cystic carcinoma and invasive lobular carcinoma of the breast.

Authors:  Anikó Kovács; Fredrik Persson; Marta Persson; Mattias K Andersson; Göran Stenman
Journal:  Mol Clin Oncol       Date:  2017-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.